News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:02 2024-04-24 pm EDT			Pre-market 08:02:24 am
48.86 ^USD	-0.27%		48.3	-1.16%

01:53pm	Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss	DJ
01:35pm	(BMY) BRISTOL MYERS SQUIBB Sees Fiscal Year 2024 EPS Range $0.40 - $0.70	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss	07:53am	DJ
Bristol Myers Squibb : Q1 2024 Results Presentation (with Appendix)	07:43am	PU
(BMY) BRISTOL MYERS SQUIBB Sees Fiscal Year 2024 EPS Range $0.40 - $0.70	07:35am	MT
Earnings Flash (BMY) BRISTOL MYERS SQUIBB Posts Q1 Revenue $11.87B, vs. Street Est of $11.45B	07:35am	MT
Bristol Myers: Q1 Earnings Snapshot	07:12am	AQ
Futures Decline Pre-Bell Ahead of Earnings, Economic Reports; Asia Churns, Europe Down	07:02am	MT
Bristol Myers Squibb Reports First Quarter Financial Results for 2024	07:00am	BU
Bristol Myers posts quarterly loss, revenue rises 5%	06:59am	RE
Futures falter as Meta Platforms weighs on megacaps	06:03am	RE
Bristol Myers Squibb : Preliminary Q1 2024 Acquired IPRD and Licensing Income Schedule	Apr. 24	PU
Germany's Evotec appoints Christian Wojczewski as CEO	Apr. 23	RE
Novartis Nominates Former Bristol Myers Squibb CEO as New Chair	Apr. 23	MT
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand	Apr. 23	MT
Novartis raises targets for 2024	Apr. 23	CF
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates	Apr. 22	RE
Bristol-Myers Squibb Signs $380 Million Deal With Cellares to Manufacture CAR T Cell Therapies	Apr. 22	MT
Bristol Myers signs $380 mln CAR-T therapies supply deal with Cellares	Apr. 22	RE
Bristol Myers signs supply agreement with Cellares	Apr. 22	CF
Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies	Apr. 22	RE
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster	Apr. 22	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST